Ublituximab
Relapsing-Remitting Multiple Sclerosis
Explore 71 assets in Relapsing-Remitting Multiple Sclerosis →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
TG Therapeutics, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07220252CT.gov Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis | — | Not Yet Recruiting | — | — | — |
NCT06864936CT.gov Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis | — | Recruiting | — | — | — |
NCT07225361CT.gov Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis | — | Recruiting | — | — | — |
NCT06629428CT.gov Effects of Ublituximab on Motor Functions in Multiple Sclerosis | — | Recruiting | — | — | — |
NCT07211633CT.gov A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) | — | Active Not Recruiting | — | — | — |
NCT05877963CT.gov Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | — | Recruiting | — | — | — |
NCT04130997CT.gov An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | — | Active Not Recruiting | — | — | — |
NCT03277261CT.gov Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) | — | Completed | — | — | — |
NCT03277248CT.gov Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) | — | Completed | — | — | — |
NCT03381170CT.gov An Extension of the TG1101-RMS201 Trial | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Relapsing-Remitting Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ublituximab (this asset) | TG Therapeutics, Inc. | Approved | BB · 66 |
| Natalizumab | Biogen | P4 | BBB |
| Fingolimod | TG Therapeutics, Inc. | P4 | BBB |
| Glatiramer | University Hospital, Montpellier | P4 | BBB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Biogen | P4 | BBB |
| Ocrelizumab | Biocad | P4 | BBB |
| 2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER | University Hospital, Montpellier | P4 | BBB |
| Cladribine | Uppsala University | P4 | BBB |
| Phytonadione, (E)-(±)- | Biogen | P4 | BBB |
+42 more in the Relapsing-Remitting Multiple Sclerosis cohort
Other indications for Ublituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Marginal Zone Lymphoma | — | P2/3 | B · 57 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | B · 56 |
| Follicular Lymphoma | — | P2/3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ublituximab in Relapsing-Remitting Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ublituximab-relapsing-remitting-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →